John_Vallay
4 weeks ago
Kjv
Based on your reply, it would seem to me that you are looking for lightning to strike.
Your investment is based on impulse and dreams, not fundamentals.
You buy $10,000 worth of ENDV stock at .002 a share means you own 5 million shares.
If the stock reaches JUST 1 PENNY A SHARE, your 5 million shares are worth $50,000 which means you would be happy with a $40,000 profit.
You may also dream of the stock reaching 2 cents a share because it was close to 2 cents a year ago, which would mean your 5 million shares would be worth $100,000 and you net a $90,000 profit.
I do not wish you ill-will, but the chances of ENDV going to 0001 is much more probable than getting to your dream numbers.
Unfortunately in the OTC sub penny world, many investors have your philosophy and get burned most of the time, but maybe you will catch the lighting in a bottle and walk away a happy person with your ENDV investment, but in my opinion you are better off going to Las Vegas and putting your $10,000 on a HARD 8.
Craig305
1 month ago
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo Therapeutics, Inc.
Thu, March 28, 2024 at 9:03 AM EDT
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million.
With completion of the APA, both Endonovo and SofPulse, Inc. share a strategic vision and a commitment for long term growth.
Finalized Terms of SofPulse, Inc. Spin-off
The APA transaction for the purchase of Endonovo assets and IP by SofPulse, Inc. is now closed, pending the customary regulatory approvals.
Key points of the APA include:
Agreement to engage Adeptus, a qualified third party's asset valuation firm.
Acquisition of ENDV IP by SofPulse Inc., including FDA-clearance in the human medical markets, for $50 Million, with potential additional valuation determined by Adeptus (which management believes will be between $50 million to $100 million).
Agreement for SofPulse Inc. to issue $50 million in freely traded stock through an S-1 registration, priced at $5.00 per share to Endonovo.
Register and distribute SofPulse Inc. shares to ENDV's shareholders with its present intention is to distribute 80% of such shares to ENDV shareholders on a date to be determined.
Any additional valuation by Adeptus over $50 million will be paid in cash or in a secured promissory note which will be convertible into NASDAQ listed marketable securities at the sole discretion of the ENDV.
Filing of S-1 registration statement to register the assets being purchased and to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.
SofPulse, Inc. Capital Raise
SofPulse, Inc. has commenced its capital raise of up to $1,000,000 through a 506(c) -offering tailored for accredited investors. The present capital offering is valued at a pre-money valuation of approximately $25.2 million, with shares priced at $2.50 per share. The capital raise is anticipated to support further development and growth. Upon completion of the capital raise, SofPulse Inc. will look to further develop the assets and IP through additional capital funding rounds to fund its path toward its IPO and NASDAQ registration.
SofPulse Inc. Drives Revenue Growth with Expanded Distribution
SofPulse® Pulsed Electro Magnetic Field (PEMF) medical technology, utilizing its FDA-clearance for the reduction of pain and edema post-operatively, helps to position the Company as a leader in the development of innovative medical devices.
To drive revenue and future expansion, SofPulse, Inc. aims to build on current marketing distribution initiatives for long-term growth and stability in the following areas:
Development of Veterans Association (VA) and Department of Defense (DoD) post-operative pain management market for SofPulse®.
Expand distribution throughout Taiwan, building on Taiwan FDA clearance.
Increase expansion efforts into other Asian markets such as Singapore, South Korea, Thailand, and Hong Kong.
Grow International distribution of SofPulse® in Mexico, Central and South America.
Re-initiate efforts to penetrate European markets with SofPulse® devices.
Expand and develop SofPulse® devices and other new PEMF medical devices for commercialization to all US hospital, surgical and rehabilitation facilities.
Endonovo Market Outlook is Extremely Positive
The Endonovo management team is excited about the completion of the APA and looks forward to the continued growth and success of Endonovo Therapeutics, Inc. through the following areas of business:
Exclusive rights to develop non-medical human PEMF IP and wellness markets.
Development of new non-medical wellness products for the expanding U.S. PEMF therapy device wellness market.
Utilization of groundbreaking multi-coil IP technology for over-the-counter PEMF product development in wellness and human markets.
Maintenance of rights to develop comprehensive telehealth division and platform (SofPulse, Inc. has signed an exclusive agreement to be a customer with a five-year contract).
Continued focus on mergers and acquisitions division to enhance product offerings for new technology and IP.
Endonovo, as business continues to expand, offers additional value to shareholders with the development of the non-medical Wellness market and other opportunities planned by the Company to sustain its long-term growth
SofPulse® PEMF Benefits and Technology Featured in The Press
SofPulse®'s effective non-pharmacological PEMF pain and inflammation management solutions were highlighted in a recent article by Wallstreetpr.com, titled "Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)." The article can be found on MarketScreener, Barchart.com, abnewswire, Benzinga, Muck Rack, The Globe and Mail, and other news outlets.
Click to view article:
https://www.marketscreener.com/quote/stock/PACIRA-BIOSCIENCES-INC-7299436/news/Beyond-the-Pill-Athletes-Champion-PEMF-and-Non-Opioid-Solutions-for-Pain-Management-ENDV-46240551/
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is currently structured into three divisions- Legacy – a commercial stage developer primarily of medical and non-medical PEMF devices and products; and its Build Up Strategy – acquiring complementary new technology industries; and its Telehealth - focused on bringing Telehealth solutions to the commercial and medical markets. In 2023, Endonovo announced the sale of their medical division and related IP for $50 Million or higher, through an Asset Purchase Agreement (APA) to SofPulse, Inc.. SofPulse Inc., a current subsidiary of Endonovo and a proposed spin-off company through the APA, plans to coordinate the use of SofPulse® and continue to commercialize innovative medical devices globally.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
sbarnes@endonovo.com
www.endonovo.com
View comments
Craig305
2 months ago
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
March 04, 2024 09:09 ET| Source: Endonovo Therapeutics, Inc.Follow
US Army Medical Research and Development Command Vendor Day
Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day.
The USAMRDC is the Army's medical materiel developer, responsible for medical research, development and acquisition. The command unit has a key role in identifying innovative pain management solutions for Veterans Administration (VA) and Department of Defense (DoD) patients and uses.
SofPulse®, along with its VA reseller, Academy Medical Inc., is planning to showcase SofPulse® and its non-evasive, drug-free pain management solution to the VA and military attendees. The Company will prepare videos, posters and printed materials to educate and demonstrate pain and inflammation reduction benefits of SofPulse® to attendees during the event.
Current SofPulse® Use and Plan for Growth in VA/DoD
Since 2019, SofPulse® has been used regularly by surgeons at the Michael DeBakey VA Medical Center in Houston to manage pain and edema following various cardiothoracic procedures. An investigator-initiated study, authored by Dr. Samir Awad, Professor of Surgery at Baylor College of Medicine, entitled “The Impact of Pulsed Electromagnetic Field (SofPulse®) on Postoperative Pain in Patients Undergoing Cardiothoracic Surgery” was accepted for oral presentation at the 44th Annual meeting of the Association of VA Surgeons in 2020. The results of the study demonstrate that the use of SofPulse® significantly decreased postoperative pain Visual Analog Scale (VAS) by 50%, decreased postoperative opioid requirements (morphine equivalent dose) by 70% and resulted in a significant decrease in Length of Stay at the hospital by a median of two days.
Ira Weisberg, President of SofPulse, Inc., said of the event: “Our goals are to increase distribution of SofPulse® throughout the entire VA/DoD health care system. This will allow our wounded warriors and veterans who served our country to recover with less pain and get back to their lives faster. We feel it is an honor that SofPulse® can embrace and be proud to be making a difference in the lives of our national heroes.”
SofPulse® Expands VA Marketing Efforts
As SofPulse® prepares for wider integration into the VA and DoD medical systems, SofPulse Inc. is planning to attend multiple VA-related pain management and surgical conventions and symposiums during 2024. In addition to being featured at the USAMRDC Vendor Day, the Company is planning to attend the 2024 Association of VA Surgeons (AMSUS) Society of Federal Health Professionals, Operational Medicine Symposium (OpMed) & Technology Showcase, Traumatic Brain Injury Conference, Military Surgical Symposium and the Special Operations Medical Association (SOMA) conferences.
Academy Medical Partnership Provides SofPulse® Path to Expand VA & DoD Use
Currently, SofPulse® devices are listed on both the prestigious Federal Supply Schedule (FSS) and the Distribution and Pricing Agreement (DAPA) by our distribution partner, Academy Medical Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB) government reseller. SofPulse® featured by Academy Medical at USAMRDC Vendor Day, offers extended exposure for the opportunity to present and demonstrate its innovative pain management solutions to multiple organizations at one time.
Weisberg, emphasized: “Our relationship with Academy Medical allows SofPulse® access to all VA and DoD medical centers nationwide to work with surgeons and staff to expand use. We are currently in several high-level discussions with various VA and DoD medical centers to initiate the use of SofPulse® at these centers. SofPulse® is being seen as a viable non-pharmacological pain management alternative for patients with both addictions to opioids and those susceptible to opioid abuse or opioid allergies. The expansion of the use of SofPulse® throughout the veterans and military healthcare systems is a top priority for our Company moving forward and can enable us to build continued market growth.”
VA Opioid Safety Initiative is Focused to Improve Pain Care Quality and Safety For Veterans
SofPulse, Inc., is committed to supporting the VA in its mission to provide high-quality, drug-free patient-centered care to veterans. The VA’s efforts to improve pain care quality and safety, such as the Stepped Care Model and the Opioid Safety Initiative, are central to the integration of SofPulse®, which offers a non-opioid pain management solution that complements existing strategies.
VA.GOV states: “The VA is committed to finding ways to manage pain in veterans while limiting the risks of long-term opioid therapy.”
In May 2022, the VA/DoD released their Clinical Practice Guidelines for the Use of Opioids in the Management of Chronic Pain to all VA Hospitals, Medical Centers, and medical providers. The report recommends medical providers assess both acute surgical and chronic pain experienced by patients regularly to discontinue or combine opioid pain management with non-opioid modalities such as devices and other drug-free options. Integrating SofPulse® into its post-operative pain management protocols, the VA can improve the quality of care and enhance the well-being of veterans nationwide.